What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 6 minute read Pharma Industry News Minerva Neurosciences gains up to $200m to advance Roluperidone toward FDA approval and U.S. market launch Minerva Neurosciences secures up to $200 million to fund a new Phase 3 trial of Roluperidone and prepare for a potential U.S. launch. Find out what’s next. bySoujanya RaviOctober 21, 2025